Treatment with a fusion protein of the extracellular domains of NKG2D to IL-15 retards colon cancer growth in mice

Journal of Immunotherapy

Volumn 37, Issue 5, 2014, Pages 257-266

  Xia, Yan ^a   Chen, Bei ^a   Shao, Xiaoqing ^a   Xiao, Weiming ^b   Qian, Li ^a   Ding, Yanbing ^b   Ji, Mingchun ^a   Gong, Weijuan ^a,b  

^a YANGZHOU UNIVERSITY   (China)

^b Department of Gastroenterology Second Clinical Medical College   (China)

Author keywords

cancer; Il 15; immunotherapy; NKG2D

Indexed keywords

ANTINEOPLASTIC AGENT; DSNKG2D IL 15 PROTEIN; HYBRID PROTEIN; INTERLEUKIN 15; NATURAL KILLER CELL RECEPTOR NKG2D; UNCLASSIFIED DRUG; KLRK1 PROTEIN, MOUSE; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; COLON CANCER; CONTROLLED STUDY; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; LYMPHOCYTE PROLIFERATION; MOUSE; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CELL GROWTH; COLONIC NEOPLASMS; DRUG EFFECTS; ESCHERICHIA COLI; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; PROCEDURES; PROTEIN ENGINEERING; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL GROWTH PROCESSES; CELL LINE, TUMOR; COLONIC NEOPLASMS; ESCHERICHIA COLI; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-15; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; PROTEIN ENGINEERING; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS;

EID: 84900527121     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000033     Document Type: Article

References (31)

1. Bauer S, Groh V, Wu J, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science. 1999;285:727-729.
2. Wu J, Song Y, Bakker AB, et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science. 1999;285:730-732.
3. Champsaur M, Lanier LL. Effect of NKG2D ligand expression on host immune responses. Immunol Rev. 2010;235: 267-285.
4. Hayakawa Y. Targeting NKG2D in tumor surveillance. Expert Opin Ther Targets. 2012;16:587-599.
5. Salih HR, Holdenrieder S, Steinle A. Soluble NKG2D ligands: prevalence, release, and functional impact. Front Biosci. 2008; 13:3448-3456. (Pubitemid 351594695)
6. Hilpert J, Grosse-Hovest L, Grünebach F, et al. Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses. J Immunol. 2012;189:1360-1371.
7. Mesiano G, Todorovic M, Gammaitoni L, et al. Cytokineinduced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Expert Opin Biol Ther. 2012;12:673-684.
8. Gong W, Xiao W, Hu M, et al. Ex vivo expansion of natural killer cells with high cytotoxicity by K562 cells modified to coexpress major histocompatibility complex class I chain-related protein A, 4-1BB ligand, and interleukin-15. Tissue Antigens. 2010;76:467-475.
9. Sutlu T, Alici E. Natural killer cell-based immunotherapy in cancer: current insights and future prospects. J Intern Med. 2009;266:154-181.
10. McKenna DH, Kadidlo DM, Cooley S, et al. Clinical production and therapeutic applications of alloreactive natural killer cells. Methods Mol Biol. 2012;882:491-507.
11. Arai S, Meagher R, Swearingen M, et al. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy. 2008;10: 625-632.
12. van Duikeren S, Fransen MF, Redeker A, et al. Vaccineinduced effector-memory CD8+T cell responses predict therapeutic efficacy against tumors. J Immunol. 2012;189: 3397-3403.
13. Steel JC, Waldmann TA, Morris JC. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol Sci. 2012;33:35-41.
14. Decot V, Voillard L, Latger-Cannard V, et al. Natural-killer cell amplification for adoptive leukemia relapse immunotherapy: comparison of three cytokines, IL-2, IL-15, or IL-7 and impact on NKG2D, KIR2DL1, and KIR2DL2 expression. Exp Hematol. 2010;38:351-362.
15. Correia MP, Costa AV, Uhrberg M, et al. IL-15 induces CD8+ T cells to acquire functional NK receptors capable of modulating cytotoxicity and cytokine secretion. Immunobiology. 2011;216:604-612.
16. Zhang M, Yao Z, Dubois S, et al. Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer. Proc Natl Acad Sci USA. 2009;106:7513-7518.
17. Mignot G, Ullrich E, Bonmort M, et al. The critical role of IL- 15 in the antitumor effects mediated by the combination therapy imatinib and IL-2. J Immunol. 2008;180:6477-6483.
18. Kaspar M, Trachsel E, Neri D. The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis. Cancer Res. 2007;67:4940-4948. (Pubitemid 46910202)
19. Kobayashi H, Dubois S, Sato N, et al. Role of transcellular IL- 15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. Blood. 2005;105:721-727. (Pubitemid 40070758)
20. Qian L, Ji MC, Pan XY, et al. Construction of a plasmid for co-expression of mouse membrane-bound form of IL-15 and RAE-1E and its biological activity. Plasmid. 2011;65: 239-245.
21. Roberts AI, Lee L, Schwarz E, et al. NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment. J Immunol. 2001;167:5527-5530. (Pubitemid 33062738)
22. Rajasekaran K, Xiong V, Fong L, et al. Functional dichotomy between NKG2D and CD28-mediated co-stimulation in human CD8+ T cells. PLoS One. 2010;5:e12635.
23. Groh V, Bruhl A, El-Gabalawy H, et al. Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc Natl Acad Sci USA. 2003;100:9452-9457. (Pubitemid 37033949)
24. Soriani A, Zingoni A, Cerboni C, et al. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NKcell susceptibility and is associated with a senescent phenotype. Blood. 2009;113:3503-3511.
25. Kohga K, Takehara T, Tatsumi T, et al. Anticancer chemotherapy inhibits MHC class I-related chain a ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma. Cancer Res. 2009;69:8050-8057.
26. Yamanegi K, Yamane J, Kobayashi K, et al. Sodium valproate, a histone deacetylase inhibitor, augments the expression of cellsurface NKG2D ligands, MICA/B, without increasing their soluble forms to enhance susceptibility of human osteosarcoma cells to NK cell-mediated cytotoxicity. Oncol Rep. 2010;24:1621-1627.
27. Zhang T, Sentman CL. Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells. Cancer Res. 2011;71:2066-2076.
28. Jakobisiak M, Golab J, Lasek W. Interleukin 15 as a promising candidate for tumor immunotherapy. Cytokine Growth Factor Rev. 2011;22:99-108.
29. Di Sabatino A, Calarota SA, Vidali F, et al. Role of IL-15 in immune-mediated and infectious diseases. Cytokine Growth Factor Rev. 2011;22:19-33.
30. Waldmann TA, Lugli E, Roederer M, et al. Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood. 2011;117:4787-4795.
31. Berger C, Berger M, Hackman RC, et al. Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood. 2009;114:2417-2426.